12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Herceptin trastuzumab: Postmarketing study data

Researchers at Vall d'Hebron University Hospital reported data from an analysis of medical records from 45 patients ages 70-92 with HER2-overexpressing breast cancer who had received >=1 dose of Herceptin showing that the drug increased the incidence of heart problems, especially in women with a history of heart disease and/or diabetes. Specifically, 8 patients experienced asymptomatic cardiotoxicity, defined as an absolute drop...

Read the full 288 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >